Compare Novartis AG (NVS) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Novartis AG trades at $143.44 (market cap $268.57B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $48.25 (market cap $561.25M). The key difference: Novartis AG is far larger — about 478.5× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Novartis AG pays a 3.31% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days on average.
| NVS | QCLN | |
|---|---|---|
Market Cap | $268.57B | $561.25M |
Volume | 1,532,573 | 323,550 |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $68.47 |
52-Week Low | $121.80 | $41.10 |
Typical Hold Time | 82 Days | 50 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
QCLN trades at $49.44, down 2.62% today but maintains a bullish technical outlook with strong moving average support. The clean energy ETF benefits from geopolitical tensions accelerating renewable energy adoption globally. Recent news highlights increased data center energy demand and political focus on clean energy policies as key growth catalysts.
The ETF's performance remains tied to U.S. political outcomes and federal energy policy, with recent outperformance against major indices. Key risks include policy uncertainty and market volatility, while institutional interest grows amid global energy security concerns and the ongoing energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
